Vicore Pharma (VCRE) announced that its Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis passed a pre-planned futility analysis. The independent Data Monitoring Committee recommended continuing without modification and raised no concerns in its separate safety and benefit-risk review.
The analysis examined the change in forced vital capacity, a lung-function measure, at 52 weeks for 100 mg twice daily versus placebo. It covered approximately the first 100 randomized patients who completed 52 weeks or discontinued, around 27% of enrollment. The pre-specified stopping criterion was conditional power below 20%; that criterion was not met. Vicore remains blinded to trial data. Enrollment finished ahead of schedule in April 2026 with 378 patients. The company expects topline results in mid-2027 and says its cash runway extends into the second half of 2028.
Vicore Pharma (VCRE) will participate in the Chardan Healthcare Conference in New York on October 20, 2026. CEO Ahmed Mousa will join a panel on idiopathic pulmonary fibrosis and chronic respiratory disease from 2:00–2:30 PM ET. The event at the Lotte New York Palace will also include one-on-one meetings.
Vicore Pharma (VCRE) increased its outstanding shares and votes by 118,916 following warrant exercises for participants in board incentive programs. The issuance followed the exercise of 117,737 share awards entitled to 118,916 shares under Board LTIP 2023, Board LTIP 2024 and Board RSU 2025.
As of September 30, 2026, total registered shares and votes stood at 281,644,509. Share capital increased by 59,457.999424 SEK to a registered total of 140,822,253.132817 SEK.
Vicore Pharma (VCRE) will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026, from 8:30 to 8:55 AM ET.
The virtual event will feature a company presentation and 1×1 meetings with CEO Ahmed Mousa, CFO Hans Jeppsson and CMO Bernt van den Blink. Vicore focuses on angiotensin II type 2 receptor agonists, including its lead oral small molecule buloxibutid for idiopathic pulmonary fibrosis (IPF), which has Orphan Drug and Fast Track designations and is in a global 52‑week Phase 2b ASPIRE trial.
Vicore Pharma (NASDAQ:VCRE, STO:VICO) announced participation in two September 2026 healthcare conferences. At the Wells Fargo Healthcare Conference at Encore Boston Harbor in Boston, the company will hold 1×1 meetings on September 8 with CEO Ahmed Mousa. At the Cantor Global Healthcare Conference at the Waldorf Astoria New York, Mousa will join a fireside chat and 1×1 meetings on September 11 from 9:45–10:15 AM ET, which will be available via webcast.
Vicore Pharma (Nasdaq US:VCRE), a clinical-stage biopharmaceutical company focused on angiotensin II type 2 receptor agonists (ATRAGs), will present at the Pareto Securities 17th Annual Healthcare Conference at Hotel At Six in Stockholm.
The company’s CFO, Hans Jeppsson, is scheduled to present on Wednesday, September 2, 2026, from 14:25 to 14:45 CEST. Vicore’s lead program, buloxibutid, an oral ATRAG for idiopathic pulmonary fibrosis, holds FDA Orphan Drug and Fast Track designations and is being studied in the 52-week Phase 2b ASPIRE trial.
Vicore Pharma (NASDAQ:VCRE, Nasdaq Stockholm:VICO) will present at the European Respiratory Society (ERS) Congress 2026, held September 5–9 in Barcelona and online. The company will share new data on the design and baseline characteristics of patients in its global 52-week Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis (IPF), and translational findings on angiotensin II type 2 receptor activation in alveolar epithelial type II cells and MMP-13.
An oral presentation on ASPIRE-IPF is scheduled for September 7, 2026 at 11:35 CEST, and a poster on buloxibutid’s AT2 receptor activation and association with fibrosis resolution will be presented September 6, 2026 at 12:30 CEST. According to Vicore Pharma, ASPIRE completed enrollment in April 2026 with over 360 patients at more than 100 sites in 14 countries, enabling topline results in mid-2027. Presentation materials will be posted on the company’s website.
Vicore Pharma (NASDAQ:VCRE), a clinical-stage biopharmaceutical company developing angiotensin II type 2 receptor agonists (ATRAGs), will participate in the Leerink Therapeutics Forum.
The event will be held on Tuesday, July 14, 2026, at the Boston Harbor Hotel in Boston, Massachusetts, and will feature 1×1 investor meetings with CEO Ahmed Mousa.
Vicore Pharma (Nasdaq US:VCRE) will begin trading American Depositary Shares (ADSs) on the Nasdaq Capital Market on July 2, 2026. Each ADS represents 10 common shares.
The Nasdaq US listing is a secondary listing, adds no new shares, and aims to expand access to US capital markets.